U.S. FDA approves J&J hepatitis C pill

November 22, 2013 11:56 PM

8 0

U.S. FDA approves J&J hepatitis C pill

(Reuters) - U.S. regulators on Friday approved the use of Johnson & Johnson's Olysio, also known as simeprevir, as a treatment for chronic infection with the liver-destroying hepatitis C virus.

Olysio, a protease inhibitor that blocks a specific protein needed by the virus to replicate, is to be used in combination with interferon, given by injection, and ribavirin, another pill.

Read more

To category page

Loading...